Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2022 AUA Annual Meeting
2022 Summit on Cancer Health Disparities
EHA2022 Congress
Digestive Disease Week 2022
2022 ASCO Annual Meeting
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Departments
ASCO Plenary Series
Adolescent and Young Adult Oncology
Announcements
Art of Oncology
ASCO State Affiliates
At Microphone 1
The Big Casino
Book Reviews
Clinical Trials Resource Guide
Direct From ASCO
Education in Oncology
End-of-Life Oncology
Expert’s Corner
FDA Update
Geriatrics for the Oncologist
Health-Care Policy
Hematology Expert Review
In Memoriam
Inside the Black Box
Integrative Oncology
In the Clinic
In the Literature
In the News
Journal Spotlight
Law and Ethics
Letters to the Editor
Living a Full Life
OCE Insights
Oncology Worldwide
Perspectives
Palliative Care in Oncology
Patient’s Corner
Pioneers in Oncology
Prevention in Oncology
Profiles
Psychosocial Oncology
Special Reports
Through the Lens of Oncology History
Women in Oncology
Advertisement
Advertisement
Jul
05
Today In Oncology
EAU22 New Research Supports Risk-Based Prostate Cancer Screening
EAU22 Study Finds Gut Microbes Differ in Patients With Prostate Cancer vs Those With Benign Biopsy Results
New Consensus-Based Guidance on Managing Cancer Pain in Patients With Opioid Use Disorder or Opioid Misuse
Trastuzumab and Nivolumab Plus Either Ipilimumab or FOLFOX as First-Line Treatment for HER2-Positive Advanced Esophagogastric Adenocarcinoma
Lisocabtagene Maraleucel as Second-Line Treatment for Relapsed or Refractory Large B-Cell Lymphoma TRANSFORM Trial
View More
Advertisement